How to start the conversation with your doctor.

Text Size A A A

HOW RAPAFLO® CAN HELP

Rapid symptom relief. Designed to target the problem. One capsule daily.

RAPAFLO works quickly to relax muscles in the prostate gland and parts of the bladder.6 This improves urine flow in a few hours and reduces uncomfortable symptoms such as frequent urination, sudden urge to urinate, waking at night to urinate, weak or interrupted stream, straining to urinate, and feeling that the bladder is not completely empty after urinating, within days.

How does RAPAFLO work?

RAPAFLO belongs to a group of drugs known as "alpha-blockers" and works by relaxing the muscles in the prostate and the bladder neck (the area where the bladder joins the urethra).3 This improves urine flow through the urethra and reduces symptoms within a few days.

Selectivity: Works Where It Counts

RAPAFLO is different from older alpha-blockers because it is designed to target the specific areas of the body involved in BPH: the prostate and the neck of the bladder. This makes RAPAFLO a highly "selective" alpha-blocker.

In medical studies, RAPAFLO provided significant relief in:

Older and younger men2
Men with severe BPH symptoms2
Men also taking other medications for cardiovascular* conditions2

Simple dosing

Most often, your doctor will prescribe one RAPAFLO capsule daily, with a meal.6 Consult with your doctor if you have any other questions about how to take RAPAFLO.

In general, if you stop treatment, BPH symptoms may return.

*Patients on alpha blockers were excluded

References

Fenter TC, Naslund MJ, Shah MB, et al. The cost of treating the 10 most prevalent diseases in men 50 years of age or older. Am J Manag Care. 2006;12(4 suppl):S90-S98
Data on file, Watson Pharma, Inc.
National Institute of Diabetes and Digestive and Kidney Diseases. Prostate enlargement: benign prostatic hyperplasia. NIH Publication No. 07-3012. June 2006.
Bruskewitz RC. Quality of life and sexual function in patients with benign prostatic hyperplasia. Rev Urol. 2003;5(2):72-80
Roberts RO, Jacobsen SJ, Rhodes T, et al. Natural history of prostatism: impaired health status in men with lower urinary tract symptoms. J Urol. 1997;157:1711-1717
RAPAFLO™ (silodosin) full prescribing information. Corona, CA: Watson Pharma Inc. October 2008.
Agency for Healthcare Quality and Research (U.S. Dept Health and Human Services): Quick Tips When Talking With Your Doctor. Available at: http://www.ahrq.gov/consumer/quicktips/doctalk.htm.
American Urological Association. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003;170:530-547
Nickel JC. Comparison of clinical trials with finasteride and dutasteride. Rev Urol. 2004;6 Suppl 9:S31-9
Benign Prostatic Hyperplasia (BPH): A Patient’s Guide. Available at: http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/patient-guides/bph_guide_2003.pdf. Accessed February 4, 2009.
National Institute on Aging: Talking With Your Doctor. Available at: http://www.nia.nih.gov/HealthInformation/Publications/TalkingWithYourDoctor/. Accessed March 5, 2009.
Medline Plus Medical Encyclopedia from NIH: Enlarged Prostate. Available at: http://www.nlm.nih.gov/medlineplus/ency/article/000381.htm. Accessed March 5, 2009.
Shvartzman P, Borkan JM, Stoliar L, et al. Second-hand prostatism: effects of prostatic symptoms on spouses’ quality of life, daily routines and family relationships. Family Pract. 2001;18:610-613.
Kuritzky L. A primary care physician’s perspective on benign prostatic hyperplasia. Rev Urol. 2003;5(suppl 5):S42-S48.
Wolters R, et al: Lower urinary tract symptoms: social influence is more important than symptoms in seeking medical care. BJU Int. 2002;90:655–661.
Rosen RC, Giuliano F, Cason CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 2005;47:824–837.
Ponholzer A, Madersbacher S. Lower urinary tract symptoms and erectile dysfunction; Links for diagnosis, management and treatment. Int J Impot Res. 2007;19:544-550.
Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006;47:362-367.
Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol. 2003;170(2 Pt 1):649-653.
Murata S, Taniguchi T, Takahashi M, et al. Tissue selectivity of KMD-3213, an alpha(1)-adrenoreceptor antagonist, in human prostate and vasculature. J Urol. 2000;164:578-583.
Stafford-Smith M, Bartz R, Wilson K, et al. Alpha-adrenergic mRNA subtype expression in the human nasal turbinate. Can J Anesth. 2007;54:549-555.
Cialis® (tadalafil) full Prescribing Information. Indianapolis IN: Eli Lilly and Co.; June 2007.
Viagra® (sildenafil) full Prescribing Information. New York, NY: Pfizer Inc. October 2006.
Levitra® (vardenafil) full Prescribing Information. Kenilworth, NJ: Schering Corporation.
McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;18:2387-2398
Issa MM, Regan T. Medical therapy for benign prostatic hyperplasia—present and future impact. Am J Manag Care. 2007;13:S4-S9.
Wei JT, Calhoun E, Jacobsen SJ. Urologic Diseases in America Project: benign prostatic hyperplasia. J Urol. 2008;179(5 Suppl.):S75-S80.
Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474.
Hernández C, Estivill E, Prieto M, et al. Nocturia in Spanish patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). Curr Med Res Opin. 2008;24(4):1033-1038
Schwinn DA, Roehrborn CG alpha-1 Adrenoreceptor subtypes and lower urinary tract symptoms. Int J Urol. 2008; 15:193-199.
http://www.dictionary.com
Atlas of Human Anatomy, Frank H. Netter, MD, Ciba-Geigy Corporation, Summit, NJ, 1989.

RAPAFLO is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).

RAPAFLO is not indicated for the treatment of hypertension.

Important Safety Information

RAPAFLO is approved to treat male urinary symptoms due to BPH, also called an enlarged prostate. RAPAFLO should not be used to treat high blood pressure. Only your doctor can tell if you have BPH, not a more serious condition like prostate cancer. RAPAFLO should not be used in patients with severe liver or kidney disease as well as those taking certain antifungal or HIV drugs. Avoid driving or hazardous tasks until you know how RAPAFLO will affect you, as a sudden drop in blood pressure may occur, rarely resulting in fainting. If considering cataract surgery, tell your eye surgeon you're currently taking RAPAFLO or have taken it in the past. Side effects include orgasm with reduced or no semen, dizziness, diarrhea, lightheadedness upon standing or sitting up abruptly, headache, swelling of the throat and nasal passages, and stuffy nose.